Skip to content

MDMA: all studies

Page 26 of 346: studies 251 to 260 of 3,454, newest first. Back to the MDMA overview

Research

Consumo de MDMA e LSD por jovens e adolescentes: efeitos nocivos para saúde mental

Revista Eletrônica Acervo Saúde October 18, 2024 Lucas Siqueira Dos Santos, João Marcos Santos Oliveira, Layane Estefany Siqueira Dos Santos

Objetivo: Analisar as consequências para a saúde mental provocadas pelo consumo do Dietilamida do Ácido Lisérgico (LSD) e metilenodioximetanfetamina (MDMA) por jovens e adolescentes. Revisão bibliográfica: Este artigo promove uma discussão e análise acerca do consumo desenfreado de LSD e MDMA por jovens e adolescentes. O crescimento exponencial do mercado ilegal do tráfico de drogas e a criação...

Human Quest for Rapture and Ecstasy

HAL October 12, 2024 Philippe Rochat preprint

A universal aspect of human psychology is the quest and cultivation of rapture states, the need to stand outside oneself (ecstasy). The question is what may drive the human need to abandon and transcend a default mode of survival to cultivate altered states of consciousness? The idea is to approach this basic question in light of what arguably sets us apart in nature: human self-consciousness...

N-tert-butoxycarbonyl-methylenedioxymethamphetamine, an methylenedioxymethamphetamine derivative, exhibits rewarding and reinforcing effects by increasing dopamine levels.

Behavioral Neuroscience October 1, 2024 Dong-Hyun Youn, Cheolmin Jo, Jin Mook Kim et al. 1 citation

An N-protected methylenedioxymethamphetamine (MDMA), N-tert-butoxycarbonyl-3,4-methylenedioxymethamphetamine (t-BOC-3,4-MDMA), contains tert-butoxycarbonyl and can remain undetected in the illicit drug market. It is a new type of precursor substance that is not a chemical intermediate and can be converted into a controlled substance, MDMA, by deprotection of the N-tert-butoxycarbonyl group....

DOI: 10.1037/bne0000593 (opens in new tab) Full text (opens in new tab) Drug abuse Addiction research Substance misuse Pharmacology

Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial.

Contemporary Clinical Trials Communications October 1, 2024 Erica Eaton, Christy Capone, Brian J Gully et al. 2 citations

Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) commonly co-occur and are associated with more severe symptomatology than either disorder alone, increased risk of suicide, and poorer response to existing treatments. A promising therapeutic intervention is the integration of 3,4-methylenedioxymethamphetamine (MDMA) and psychotherapy. The Food and Drug Administration (FDA)...

Zinc Mitigates MDMA-Prompted Apoptosis by Alteration of Cross Talk Among Bcl-2, Bax and P53 Genes Expression in Mouse Sertoli and Leydig Cell Lines.

Reports of biochemistry & molecular biology October 1, 2024 Salar Mahmoudi-Nejad, Isa Abdirad, Morteza Bagheri

3,4-methylenedioxymethamphetamine (MDMA) affects the male reproductive system. We investigated the mRNA levels of bax, bcl-2, and p53 genes in MDMA-induced apoptosis in mouse Sertoli (TM4) and Leydig (TM3) cells before and after taking Zinc. The TM3 and TM4 cells were cultured in four groups: I (untreated medium), II (medium with 5 mM MDMA), III (medium with 8 µM Zinc), and IV (medium with 8 µM...

MDMA for treatment of PTSD and neurorehabilitation in military populations

Neurorehabilitation September 27, 2024 Walter Dunn, Anya K. Bershad, David E. Krantz et al. 2 citations

BACKGROUND: Neurorehabilitation in military populations is complicated by higher rates of PTSD and unique characteristics of military institutions. These factors can adversely impact the patient-therapist therapeutic alliance and engagement with the rehabilitation process leading to poorer outcomes. MDMA is a non-classical psychedelic with pro-social and fear regulating properties....

DOI: 10.3233/nre-230270 (opens in new tab) Full text (opens in new tab) MDMA Neurorehabilitation Alliance Psychotherapist +1

Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine.

Journal of Pharmacology and Experimental Therapeutics September 18, 2024 Candace B Johnson, Donna Walther, Matthew J. Baggott et al. 5 citations

3,4-Methylenedioxymethamphetamine (MDMA) has shown efficacy as a medication adjunct for treating post-traumatic stress disorder (PTSD). However, MDMA is also used in nonmedical contexts that pose risk for cardiovascular and neurologic complications. It is well established that MDMA exerts its effects by stimulating transporter-mediated release of the monoamines 5-hydroxytryptamine (5-HT),...

Back to the drawing board for Lykos' MDMA therapy

The Brown University Child & Adolescent Psychopharmacology Update September 12, 2024 Alison Knopf 1 citation

The Food and Drug Administration (FDA) did not accept the application of Lykos Therapeutics for MDMA as a treatment for post‐traumatic stress disorder (PTSD). In a letter dated Aug. 9 and released by Lykos Therapeutics, the for‐profit arm of the Multidisciplinary Association for Psychedelic Studies (MAPS), the company stated that it is disappointed in the FDA response, but that it intends to...

Evaluation of an electrochemical sensor and comparison with spectroscopic approaches as used today in practice for harm reduction in a festival setting-A case study: Analysis of 3,4-methylenedioxymethamphetamine samples.

Drug Testing and Analysis September 1, 2024 Eric Deconinck, Marie A Polet, Michaël Canfyn et al.

More and more countries and organisations emphasise the value of harm reduction measures in the context of illicit drug use and abuse. One of these measures is drug checking, a preventive action that can represent a quick win by tailored consultation on the risks of substance use upon analytical screening of a submitted sample. Unlike drop-in centres that operate within a fixed setting,...

DOI: 10.1002/dta.3625 (opens in new tab) Full text (opens in new tab) 3,4‐Methylenedioxymethamphetamine MDMA Atr–nir Drug checking Electrochemical detection +1

Acute psychotropic, autonomic, and endocrine effects of 5,6-methylenedioxy-2-aminoindane (MDAI) compared with 3,4-methylenedioxymethamphetamine (MDMA) in human volunteers: A self-administration study.

Drug Testing and Analysis September 1, 2024 Verena Angerer, Yasmin Schmid, Florian Franz et al. 6 citations

The acute psychoactive, autonomic, and endocrine effects of the new psychoactive substance (NPS) 5,6-methylenedioxy-2-aminoindane (MDAI; 3.0 mg/kg, range 180-228 mg) were investigated in six healthy volunteers (four males, two females) in a non-blinded fashion without placebo. Subjective, cardiovascular, and endocrine responses were compared with two different doses of...

DOI: 10.1002/dta.3622 (opens in new tab) Full text (opens in new tab) Entactogens New psychoactive substances Pharmacokinetics Psychometric